



## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

10/518817

Application of: BAILEY, Andrew, et al.  
US Application No: Not yet allocated

DT09 Rec'd PCT/PTO 20 DEC 2004

PCT Application No: PCT/SE03/01078  
PCT Filed: June 23, 2003

For: **New Use of Pyrimidine-or Triazine-2-Carbonitiles for Treating Diseases Associated with Cysteine Protease Activity and Novel Pyrimidine-2-Carbonitile Derivatives**

Examiner: Not yet allocated  
Group Art Unit: Not yet allocated

---

Mail Stop PCT  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith a list of patents and publications that Applicants believe may be material to the patentability of claims of the above-identified application and for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56. Copies of the references, excluding US patents and publications, are also enclosed.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed together with the filing under 35 U.S.C. § 371 of the national stage of an international application and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 26-0166.

Respectfully submitted,



Jianzhong Shen  
Agent for Applicants  
Reg. No. 48,076  
Telephone: 302/886-8854

Dated: December 20, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

<i>Complete if Known</i>	
Application Number	61/09 Rec'd PCT/PTO Not Yet Assigned 20 DEC 2001
Filing Date	10/518817
First Named Inventor	Andrew Bailey
Art Unit	Not Known
Examiner Name	Not Known

Sheet 1 of 1 Attorney Docket Number 100727-1P US

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	International Search Report				
	B2	WO 03020278 A1	March 13, 2003	Novartis Pharma GMBH		
	B3	WO 0232879 A1	April 25, 2002	Naeja Pharmaceutical Inc.		
	B4	WO 9709315 A1	March 13, 1997	Signal Pharmaceuticals, Inc.		
	B5	WO 0055125	Sept. 21, 2000	Axys Pharmaceuticals, Inc.		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*